Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study: Assessing VIX001 Safety, Efficacy, and Dosing in Post Acute COVID-19 Syndrome (PACS) Patients With Neurological Symptoms and Cognitive Impairment.

NCT05947617 is registered in ClinicalTrials.gov with Neobiosis, LLC as lead sponsor.

NCT NCT05947617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05947617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study: Assessing VIX001 Safety, Efficacy, and Dosing in Post Acute COVID-19 Syndrome (PACS) Patients With Neurological Symptoms and Cognitive Impairment.
Lead sponsor
Neobiosis, LLC
Phase
Phase 1
Overall status
Unknown status
Start date
October 1, 2023
Completion date
September 1, 2025
Enrollment
9 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive impairment, neurological complication, post-acute covid-19 syndrome